Increased Radiation Pneumonitis after Crizotinib and Concurrent Thoracic Radiotherapy in Patients with ALK-positive Non-small-cell Lung Cancer

Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) and its administration has achieved considerable success. Preclinical studies have demonstrated crizotinib in combination with radiation could enhance the inhibitory effect on ALK-positive NSCLC. Radiation pneumonitis is a dose limiting toxicity of...